| AME |
Report |
Adjusted EPS |
BEAT |
pred ~$2.03 vs. cons $1.99 |
MEDIUM |
| AME |
Report |
Revenue |
BEAT |
pred ~$1.98B vs. cons $1.96B |
MEDIUM |
| AME |
Report |
Organic orders growth |
BEAT |
pred ~12% vs. cons 10% |
LOW |
| AME |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$2.05 vs. cons $2.00 (2026 Q3) |
MEDIUM |
| AME |
Guide |
Adjusted EPS guidance |
LOWER |
guide ~$8.12 vs. cons $8.14 (FY2026) |
MEDIUM |
| AME |
Guide |
Total sales growth guidance |
BETTER |
guide ~9.0% vs. cons 8.2% (FY2026) |
LOW |
| AME |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| AME |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A Q2 EPS beat of ~$0.04 versus consensus is likely to drive the initial gain, but FY2026 guidance of ~$8.12 versus consensus of $8.14 implies slightly weaker second-half earnings math and limits upward estimate revisions. |
MEDIUM |